|
  
- 现金
- 3700 元
- 精华
- 16
- 帖子
- 1790
- 注册时间
- 2002-12-9
- 最后登录
- 2021-4-14
|
1楼
发表于 2005-3-8 09:31
Viral Hepatitis in Drug Discovery & Development Conference to Take Place
March 22-23, 2005 in Princeton, NJ
PRINCETON, N.J., March 4 /PRNewswire/ -- Chronic hepatitis C (HCV) and B
(HBV) are the most common causes of chronic viral hepatitis in the United
States, posing serious risks for long-term medical complications, especially
if left untreated. HBV affects over 2 billion people in the world today
while
HCV affects approximately 4 million people each year. With this in mind,
Strategic Research Institute announces the "Annual Viral Hepatitis in Drug
Discovery & Development Summit" scheduled to take place March 22-23, 2005 in
Princeton, NJ.
By attending this industrial and networking conference you will be able
to
interact with many of the leading research scientists and decision-makers
from
the pharmaceutical/biotech industry, public health, and academic communities
working in the area of viral hepatitis of North America and internationally.
Some of the topics covered at the event include interferon mechanisms, HCV
protease inhibitors, HCV polymerase inhibitors, novel advances in HBV
therapeutics and other HCV targets/agents.
Some of the participating companies include Anadys Pharmaceuticals which
is the conference lead sponsor, Merck, Schering-Plough, Pfizer, Gilead,
Idenix
Pharmaceuticals, Bristol-Myers Squibb, Vertex Pharmaceuticals, Rigel, Roche,
Medivir, Innogenetics, Valeant Pharmaceuticals and many more.
To request a copy of the conference agenda in PDF format, please contact
the conference organizer Glenn Pascual of Strategic Research Institute at
[email protected] or 212.967.0095, ext. 245. Please include full
contact information |
|
